Mr. Liu Jian, Deputy Director General of the Department of International Cooperation of China National Intellectual Property Administration, visited OLYMVAX for investigation and guidance.
On January 4, 2023, Liu Jian, Deputy Director General of the Department of International Cooperation of China National Intellectual Property Administration, Li Yi, Level II Inspector of Sichuan Intellectual Property Service Promotion Center, Feng Lei, Director of International Cooperation Department (Publicity and Education Center) of Sichuan Intellectual Property Service Promotion Center, Wei Xing, Level IV Investigator of International Cooperation Department (Publicity and Education Center) of Sichuan Intellectual Property Service Promotion Center and other leaders visited OLYMVAX to investigate and guide the work of foreign intellectual property rights, and warmly received by Fan Fan, Vice Chairman of OLYMVAX and Director of the Research Institute, and Wu Wei, Secretary of the Board of Directors of OLYMVAX and other people.
Group Photo
First of all, Mr. Wu Wei gave a detailed introduction and report on the overall situation of OLYMVAX and the efforts made in intellectual property rights, and Inspector Li Yi and Director Feng Lei expressed their affirmation on the IPR achievements of the Company and gave guidance and expectations for the Company’s future work and development in intellectual property.
At the same time, Ms. Fan Fan introduced the development achievements and intellectual property rights of OLYMVAX in the field of biological vaccines to the investigation team in detail. It is also mentioned that under the leadership of Chairman Fan Shaowen, OLYMVAX has attached great importance to brand and patent protection. The Company has obtained 3 production approval numbers in 10 years, with outstanding research and transformation capabilities.
Deputy Director General Liu Jian said that the Department of International Cooperation of China National Intellectual Property Administration has always provided strong support for the development of enterprises in the complex international business environment based on the actual needs of enterprises. After this visit, he not only got a clear understanding of the fruitful achievements of OLYMVAX in independent innovation and intellectual property protection in the field of vaccines, but also experienced the vaccine innovation OLYMVAX. He hoped that the biological enterprises represented by OLYMVAX will continue to strengthen independent innovation, attach great importance to intellectual property rights, and actively promote the transformation and application of innovative achievements. The Department of International Cooperation of China National Intellectual Property Administration will provide more high-quality and efficient services based on actual developmental needs to help enterprises “go global” and “bring in”.
Deputy Director General Liu Jian and his delegation visited the OLYMVAX Research Center.
Subsequently, Deputy Director General Liu Jian and his delegation visited OLYMVAX Research Institute. After listening to the report on the 13-year development history, current status of core vaccine business, business layout, technological innovation and future development planning of OLYMVAX, he highly appraised the dual wheel drive strategy of leveraging the strengths of innovative vaccine development and traditional vaccine upgrading, the R&D mode of laying equal stress on independent development and joint development, and the achievements made by OLYMVAX in the vaccine field in recent years, and encouraged OLYMVAX to continue to develop bigger and stronger along this path.
Deputy Director General Liu Jian and his delegation visited the OLYMVAX Research Center.
In the Research Institute, the investigation team took a closer look, and had a detailed understanding of the equipment and technologies related to the research and development of human vaccines, and made an in-depth exchange with the investigators.
At present, OLYMVAX has 3 marketed products, 2 products under clinical trial, and more than 100 patents. In the future, OLYMVAX will continue to keep the same pace with the development of times, focusing on the three major fields of bacterial vaccines, viral vaccines and nucleic acid vaccines, and building cutting-edge technology platforms including recombinant genetic engineering technology platform and new high-end adjuvant and immunosuppressant technology platform. OLYMVAX will further strengthen branding efforts and IPR protection, and make more contributions to the high-quality development of China’s vaccine industry.